Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal

Abstract

There were no significantly increased postoperative complications after ileostomy closure in patients who received infliximab or other immunosuppressive medications compared with patients who did not.

Meta‐analysis: peri‐operative anti‐TNFα treatment and post‐operative complications in patients with inflammatory bowel disease

“…Thirteen studies were found on patients with UC, five of which were excluded based on a low NOS score . Four studies reported a mixed cohort of IBD patients, one of which was excluded due to a low NOS score . Overall, 18 studies with 4659 participants were eligible for meta‐analysis .…”

“…[25][26][27][28][29] Four studies reported a mixed cohort of IBD patients, one of which was excluded due to a low NOS score. 30 Overall, 18 studies with 4659 participants were eligible for meta-analysis. 22,[31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47] Infectious complication rates could be calculated for 16 of these studies, non-infectious complications for 14, and total complication rates for 15 studies.…”

Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy

“…Biological therapy has raised concern among surgeons regarding the risk of postoperative complications and, in particular, the risk of anastomotic leakage. Studies addressing these concerns have conflicting results.…”

Pre‐operative use of anti‐TNF‐α agents and the risk of post‐operative complications in patients with Crohn's disease – a nationwide cohort study

“…13 Other studies, with fewer exposed CD patients, have not found increased risk of different post-operative outcomes after use of anti-TNFa agents. [14][15][16] The association between anti-TNF-a agents and post-operative complications has also been examined in studies not separating the analyses to only CD patients, [17][18][19] while others included patients treated both pre-and post-operatively. [20][21][22] In this nationwide Danish cohort study of patients having intestinal resection for CD, we aimed to examine the risk of 30 and 60 days post-operative complications after use of anti-TNF-a agents within 12 weeks before surgery.…”